CIK 0000072444
- Accelerated filer
- Smaller reporting company
Vaxart, Inc.
Sign in to watch- Ticker
- VXRT
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 591212264
- Phone
- +1 650-550-3500
- Business address
- 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
- Former names
- Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2011-04-01 | FAHIM RAAFAT E F President, CEO and CFO | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2011-04-01 | Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops | Sale | −6,300 | $5.80 | $37K | 41,050 |
| 2011-04-01 | Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops | Grant or award | +30,000 | 71,050 | ||
| 2011-04-01 | Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops | Grant or award · Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2011-04-01 | Kessler Paul D. SVP Clinical, Med. & Reg.; CMO | Grant or award | +36,000 | 131,267 | ||
| 2011-04-01 | Kessler Paul D. SVP Clinical, Med. & Reg.; CMO | Grant or award · Stock Option (right to buy) | +90,000 | 90,000 | ||
| 2011-03-15 | Aryeh Jason Director | Sale | −4,900 | $5.87 | $29K | 131,783 |
| 2011-03-14 | Aryeh Jason Director | Sale | −2,400 | $5.82 | $14K | 137,683 |
| 2011-03-14 | Aryeh Jason Director | Sale | −1,000 | $5.86 | $6K | 136,683 |
| 2011-03-11 | Aryeh Jason Director | Sale | −9,900 | $5.74 | $57K | 154,883 |
| 2011-03-11 | Aryeh Jason Director | Sale | −9,900 | $5.75 | $57K | 144,983 |
| 2011-03-11 | Aryeh Jason Director | Sale | −4,900 | $5.80 | $28K | 140,083 |
| 2011-01-05 | FAHIM RAAFAT E F President, CEO and CFO | Sale | −3,181 | $5.65 | $18K | 330,637.94 |
| 2011-01-05 | Kessler Paul D. SVP Clinical, Med. & Reg.; CMO | Sale | −2,985 | $5.65 | $17K | 95,267 |
| 2010-12-27 | Aryeh Jason Director | Sale | −15,093 | $5.74 | $87K | 0 |
| 2010-12-15 | Aryeh Jason Director | Sale | −1,907 | $5.74 | $11K | 15,093 |
| 2010-12-15 | Aryeh Jason Director | Sale | −1,907 | $5.74 | $11K | 179,876 |
| 2010-12-08 | Aryeh Jason Director | Sale | −4,705 | $5.49 | $26K | 181,783 |
| 2010-12-01 | Aryeh Jason Director | Sale | −6,700 | $5.53 | $37K | 186,488 |
| 2010-11-30 | FAHIM RAAFAT E F President, CEO and CFO | Other acquisition | +3,023 | $4.30 | $13K | 336,756.94 |
Page 27 of 42 · 830 trades